laitimes

Jiuan Medical is expected to achieve a net profit of 850 million yuan to 1.15 billion yuan in the fourth quarter of 2021

author:China Securities Journal

Guo Jiying, China Securities News, China Securities Network

China Securities Network News (reporter Guo Jiying) on January 20, Jiuan Medical after the opening of the stock price rose rapidly, 9:43 a.m. up and down, the end of the day closed at 77.66 yuan / share, trading volume of 648,200 lots, turnover reached 4.918 billion yuan.

On the evening of January 19, Jiuan Medical disclosed its 2021 performance forecast, and it is expected that the net profit attributable to the mother in 2021 will be 900 million yuan to 1.2 billion yuan, an increase of 271.4% to 395.19% year-on-year; the net profit deducted from the non-attributable mother will be 850 million yuan to 1.15 billion yuan, an increase of 243.46% to 364.68% year-on-year.

Jiuan Medical said that in 2021, due to the impact of the global new crown pneumonia epidemic, the company's new coronavirus (SARS-CoV-2) antigen home self-test OTC kit product sales performance in the US market increased significantly, prompting a significant increase in operating performance in 2021.

According to the third quarter report of Jiuan Medical in 2021, the company achieved a net profit attributable to the mother of 50.128 million yuan in the first three quarters of 2021. Based on this calculation, the company's net profit attributable to the mother in the fourth quarter of 2021 can reach 850 million yuan to 1.15 billion yuan.

It is worth noting that between 2013 and 2019, jiuan medical net profit attributable to the mother after deducting non-deductions for seven consecutive years was a loss.

Jiuan Medical suggested in the 2021 performance forecast that its 2021 operating performance mainly depends on the new crown test reagent, and whether the future performance can continue to maintain rapid growth mainly depends on the progress of epidemic prevention and control in the United States, the choice of new crown testing products in the United States, the market competitiveness of the company's products and channel sales capabilities, and the future development of conventional businesses, which has great uncertainty.

Read on